vimseltinib (DCC-3014) / Deciphera, Ono Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vimseltinib (DCC-3014) / Ono Pharma
2020-004883-25: This is a multicenter, randomized, Phase 3 study with vimseltinib or placebo in patients with Tenosynovial Giant Cell Tumor, consisting of 2 parts: Part 1 is double blinded and Part 2 is open label study

Not yet recruiting
3
120
Europe
vimseltinib, DCC-3014, Capsule
Deciphera Pharmaceuticals, LLC, DECIPHERA PHARMACEUTICALS, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, TGCT is a rare tumor arising from the joints (i.e. synovium of joints, bursae, and tendon sheaths), Diseases [C] - Cancer [C04]
 
 
MOTION, NCT05059262: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26

Download Options